How Piramal Pharma Supports Women at Work: Benefits, Flexibility, and Leadership Development

Flexibility in pharma is genuinely difficult. Manufacturing, quality control, and R&D functions require physical presence in ways that a software company never faces. That context matters when evaluating how Piramal Pharma structures its work arrangements, because the flexibility it offers is built around operational reality, not just HR aspiration.

Hybrid and Remote Options

Based on employee-reported data, Piramal Pharma operates across a spectrum of work arrangements:

• Hybrid work: Approximately 21% of employees work in a hybrid model, combining office and remote days
• Work from home: Around 3% of roles are fully remote on a permanent basis
• Flexible timings: 53% of employees report flexible work timings, with the standard office window running from 9 AM to 5:30 PM or 9 AM to 6 PM
• Manager-agreed schedules: At Piramal Pharma Solutions (the CDMO arm), flexible work schedules are available upon agreement with a line manager, giving employees a degree of personalized control

The majority of roles (approximately 76%) remain office-based, which reflects the nature of pharmaceutical manufacturing and laboratory work. The honest implication: flexibility is more accessible in corporate, commercial, and support functions than on the plant floor.

Why This Matters for Women in Pharma

Inflexible scheduling is one of the most cited reasons women leave mid-career in science and pharmaceutical roles. The ability to negotiate a hybrid schedule or adjust start times accommodates caregiving responsibilities, reduces commute burden, and supports the kind of sustained career continuity that leads to senior roles.

“Beyond formal return support, we embed flexibility and choice into career planning. This includes flexible work options, role design that accommodates changing life stages and access to leadership development opportunities even when life demands shift. These mechanisms address real career inflection points and enable women to sustain and accelerate growth rather than plateau mid-career,” Nandini Piramal as quoted in Outlook Business. (https://www.outlookbusiness.com/corporate/us-biotech-funding-rising-ma-signal-gradual-cdmo-revival-nandini-piramal?utm_source=chatgpt.com )

The flexibility framework at Piramal Pharma is not unlimited, but it is structured, transparent, and backed by a leadership team that has made work-life balance a named pillar of its employer brand.

Flexible work and supportive benefits are necessary but not sufficient. The real test of an employer's commitment to women in pharma is whether women actually advance. PPL has structured its leadership development programs to address the specific pipeline gaps that prevent talented women from reaching senior roles.

The DIBA Framework

Piramal Pharma's diversity initiatives operate under a formal Diversity, Inclusion, Belonging and Accessibility (DIBA) framework. This is not a standalone HR program but a set of guidelines that shape hiring, promotion, and talent development decisions across the organization. DIBA operationalizes the company's non-discrimination principles into practical processes, covering gender, age, disability, caste, religion, and nationality.

The leadership pipeline argument at PPL starts at the very top. Nandini Piramal, the company's Chairperson, has been recognized among India's Most Powerful Women by Business Today in 2020, 2022, 2023, and 2024, and by Fortune India in both 2025 and 2026 in their 100 Most Powerful Women list. She was named a Young Global Leader by the World Economic Forum in 2014.

This matters beyond symbolism. Research consistently shows that visible women in senior leadership roles improve the career ambitions and retention rates of junior women employees. At PPL, the most senior strategic position in the company is held by a woman, which shapes organizational culture from the top down.

The evidence assembled here points to a company that is making genuine, measurable progress on the employer experience for women in pharma. The combination of flexible work arrangements, structured peer support through Women's Circles, a formal DIBA framework with published targets, and external recognition from credible independent bodies creates a picture that is more substantive than most employer brand narratives in the sector.

Three things stand out as differentiators worth noting:

1. Transparency on gaps. PPL publishes the fact that women hold 10% of top management positions and sets a 15% target. Most organizations do not disclose the gap; they only promote the progress. That honesty is a stronger signal of intent than any award.
2. A woman at the top. Nandini Piramal's role as Chairperson is not just symbolic. Her direct oversight of HR, Finance, Risk, IT, and Quality functions means that inclusion priorities have a direct line to the most senior strategic decision-maker in the company.
3. Pipeline investment at entry. With 63.3% of campus hires being women, PPL is building the future it wants. The question for the next five years is whether those entry-level hires are retained and developed into the leadership positions the DIBA framework is targeting.

For women in pharmaceutical sciences, quality, R&D, commercial, or corporate functions looking for an employer that combines global scale with a documented commitment to inclusion, Piramal Pharma's profile warrants serious consideration.

Explore open roles and learn more about life at Piramal Pharma at the Careers page.